Abbreviated Name

BLADDER-PRE-VAL

Lead Investigator

Cairns, Paul — Fox Chase Cancer Center

Coordinating Investigator

Feng, Ziding — Fred Hutchinson Cancer Center

Involved Investigators

• Feng, Ziding — Fred Hutchinson Cancer Center
• Kibel, Adam — Brigham and Womens Hospital
• Wei, John — University of Michigan Recruiting
• Wagner, Andrew — Beth Israel Deaconess Medical Center
• Sidransky, David — Johns Hopkins University
• Leach, Robin J — University of Texas Health Science Center at San Antonio
• Srivastava, Sudhir — National Cancer Institute
• Sanda, Martin — Emory University
• Czerniak, Bogdan — The University of Texas MD Anderson Cancer Center
• Schoenberg, Mark P. — Johns Hopkins University
• Cairns, Paul — Fox Chase Cancer Center

Abstact

Study never Launched

Aims

This study will test the sensitivity of gene methylation in the presence of clinically evident, pathologically confirmed bladder cancer. This study will test the specificity of gene methylation in two groups of participants without bladder cancer - requiring cystoscopy for hematuria and for foreign body (urinary stones, stents, and catheters) or infection.

Analytic Method

Quantitative real time methylation specific PCR (qMSP) of urine sediment DNA using a panel of several methylated gene markers.

Biomarkers

• No biomarkers available at this time for this protocol

Data Collections

• No data available at this time for this protocol

Protocol ID

226

Protocol Type

Collaboration

Field of Research

Hypermethylation

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of bladder

Phased Status

1